Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair loss reported on semaglutide is real, but the most common explanation people reach for — that the medicine itself attacks hair follicles — is almost certainly wrong. What the evidence points to instead is a well-recognised process triggered by rapid weight loss, not by semaglutide directly. This is a prescription-only medicine; a clinician assesses suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When people notice clumps of hair on the shower tray a few months into treatment, the instinct is to blame the injection. That reaction is understandable, and it is worth acknowledging, finding that your hair is thinning while you are trying to improve your health feels like an unfair trade. But the mechanism almost certainly runs through the weight loss itself, not through semaglutide's chemistry.
The condition is called telogen effluvium. Hair grows in cycles, and a significant physical stressor (surgery, illness, childbirth, crash dieting, or any sustained calorie deficit) can push a large proportion of hair follicles into a resting phase simultaneously. Two to four months later, those hairs shed together. The trigger was the stressor; the shedding is the delayed echo. Losing ten to fifteen percent of body weight in a short window is, to the body, exactly that kind of stressor, regardless of how the weight was lost.
The NHS patient guidance on semaglutide does not list hair loss among the medicine's direct side effects. Clinical trial data for Wegovy similarly did not flag follicular damage as a pharmacological effect. That does not mean patients are imagining it (they are not) but it does shift where the solution sits. You can read more about the Wegovy treatment overview for broader context on how the medicine works.
Telogen effluvium is dose-dependent on the severity of the nutritional stress. People who lose weight quickly while eating too little protein are more likely to experience noticeable shedding, and for longer. The follicle needs amino acids (keratin is a protein, after all) and when total intake drops steeply, the body deprioritises hair growth in favour of organs that matter more acutely.
On semaglutide, appetite suppression is the mechanism doing the therapeutic work, but it also makes hitting protein targets harder. A patient eating seven hundred calories because they simply have no hunger may be losing weight rapidly while inadvertently starving their follicles. Strength-based physical activity, which helps preserve lean muscle during a deficit, carries a secondary benefit here: the habits that protect muscle generally protect hair too.
Practical steps most prescribers and dietitians recommend include spreading protein across meals rather than concentrating it in one sitting, prioritising protein-dense foods even on low-appetite days, and ensuring iron and ferritin levels are checked if shedding is pronounced, low ferritin is an independent risk factor for hair shedding that sometimes surfaces when rapid weight loss triggers a routine blood screen. If you want a thorough look at how Wegovy and hair changes are connected, that page brings together the evidence on nutrition, shedding timelines, and what patients can do. This is a conversation worth having with your prescriber before adjusting treatment.
If you are weighing up treatment options more broadly, the weight-loss treatment overview covers the range of approaches available through private prescription in the UK.
In most cases, telogen effluvium is self-limiting. Once the body adjusts to the new weight or the rate of loss slows, follicles cycle back into their active growing phase. For many people this happens within three to six months of peak shedding, though the exact timeline varies. Hair regrowth can take longer to become visible than the shedding takes to stop.
There are signals worth taking seriously. If shedding is severe, progressing rather than plateauing, accompanied by scalp changes such as redness or scaling, or if it continues beyond six months without any sign of slowing, a GP or dermatologist should rule out other causes, alopecia areata, thyroid dysfunction, and iron-deficiency anaemia can all coincide with, or be unmasked by, the period of rapid weight change. The detailed page on whether semaglutide causes hair loss explores the differential further.
The MHRA's Yellow Card scheme allows patients to report any suspected side effects from prescription medicines, including hair changes, doing so contributes to the post-market surveillance that keeps prescribing information current. If you have specific questions about your own situation, what patients on Wegovy report about hair shedding may also be useful reading, alongside a conversation with your prescriber.
Hair shedding affects a minority of people on semaglutide, and for most who do experience it, the episode is temporary. It is not a reason to avoid clinically appropriate treatment if the benefits to your health are significant. The right response is informed preparation: adequate protein from the start, monitoring rather than alarm if some shedding appears, and open communication with your prescribing team.
Our prescribers at nume review every patient's circumstances individually before and during treatment, queries like this one are exactly what those check-ins are for. If you are researching newer agents, the cagrilintide-semaglutide combination under trial is a separate molecule with its own emerging evidence base. For questions specific to Wegovy's side-effect profile, if you want to understand whether you are likely to lose hair on Wegovy, the dedicated page goes deeper on reported rates and patient experience.
Semaglutide is a prescription-only medicine. If you think it may be appropriate for you, check your eligibility with a free consultation, a GPhC-registered prescriber, not software, reviews every application the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.